The Medicines Company
8 Sylvan Way
Parsippany
New Jersey
07054
United States
Tel: 973-290-6000
Fax: 973-656-9898
Website: http://www.themedicinescompany.com/
Email: contactus@themedco.com
About The Medicines Company
The Medicines Company's purpose is to save lives, alleviate suffering and contribute to the economics of healthcare by focusing on 3,000 leading acute/intensive care hospitals worldwide. Its vision is to be a leading provider of solutions in three areas: acute cardiovascular care, surgery and perioperative care, and serious infectious disease care. The company operates in the Americas, Europe and the Middle East, and Asia Pacific regions with global centers today in Parsippany, NJ, USA and Zurich, Switzerland.
501 articles about The Medicines Company
-
The Medicines Company Announces Recommendation by Independent Data Monitoring Committee to Continue Inclisiran Phase III Trials Following Fourth Review of Unblinded Data
10/1/2018
More than 1,899 patient-years of safety data accumulated to date – a five-fold increase over total patient exposure through Phase II trials
-
The Medicines Company Reports Second-Quarter 2018 Results
8/1/2018
The Medicines Company (NASDAQ:MDCO) today reported its financial results for the second quarter ended June 30, 2018.
-
The Medicines Company to Announce Second-Quarter 2018 Financial Results on August 1
7/26/2018
The Medicines Company will host a conference call and audio webcast on Wednesday, August 1, 2018, at 8:30 a.m. EDT
-
The Medicines Company Announces Recommendation by Independent Data Monitoring Committee to Continue Inclisiran Phase III Trials Following [Third] Review of Unblinded Data
6/27/2018
More than 1,550 patient-years of safety data accumulated to date – a three-fold increase over total patient exposure through Phase II trials
-
New Data Presented at the American Diabetes Association 78th Scientific Sessions® Reinforce the Potential of The Medicines Company’s inclisiran in Patients with Diabetes
6/26/2018
The data showed that a subcutaneous injection of 300 mg of inclisiran given at Day-1 and Day-90 lowered LDL-cholesterol (LDL-C) at Day-180 by more than 50% in patients with atherosclerotic cardiovascular disease (ASCVD) and those considered ASCVD-risk equivalents, regardless of whether those patients had diabetes.
-
The Medicines Company Presents New Data at the National Lipid Association Scientific Sessions
4/30/2018
The Medicines Company presented important new data and analyses from the ORION development program for inclisiran at the National Lipid Association (NLA) 2018 Scientific Sessions held in Las Vegas, NV.
-
The Medicines Company Reports First-Quarter 2018 Results
4/25/2018
The Medicines Company today reported its financial results for the first quarter ended March 31, 2018.
-
The Medicines Company to Announce First-Quarter 2018 Financial Results on April 25
4/19/2018
The Medicines Company will host a conference call and audio webcast on Wednesday, April 25, 2018, at 8:30 a.m., Eastern Time, to discuss first-quarter 2018 financial results and operational developments.
-
The Medicines Company Announces Chief Financial Officer Transition
3/28/2018
The Medicines Company announced the appointment of Christopher Visioli as Chief Financial Officer and Treasurer of the Company, effective immediately.
-
Sanofi and Regeneron have cut deals to dramatically reduce the price of their new cholesterol drug Praluent.
-
The Medicines Company Appoints Dr. Sarah Schlesinger to Its Board of Directors
2/27/2018
Dr. Schlesinger has spent more than 20 years working in the field of cellular immunity.
-
The Medicines Company Reports Fourth-Quarter and Full-Year 2017 Business and Financial Results
2/21/2018
The Medicines Company today reported its financial results for the fourth quarter and full year ended December 31, 2017.
-
The Medicines Company Release: Inclisiran’s First Pivotal Trial Achieves Target Enrollment Ahead of Schedule
1/25/2018
The Medicines Company today announced that the target of 1,500 patients randomized in the ORION-11 trial has been exceeded in 11 weeks – considerably beating its goal of 28 weeks.
-
The Medicines Company Announces Closing of Divestiture of Infectious Disease Business Unit to Melinta Therapeutics
1/8/2018
The Company expects to provide additional details regarding its cash position and plans as part of its fourth quarter and full year 2017 financial results.
-
Melinta Therapeutics Completes Acquisition of The Medicines Company’s Infectious Disease Portfolio
1/8/2018
The close of the acquisition solidifies Melinta’s position as the world’s largest pure-play antibiotics company.
-
The Medicines Company to Host Investor Day on January 23, 2018
12/13/2017
The Medicines Company announced that it will host an Investor Day on Tuesday, January 23, 2018, from 10:00 a.m. to 12:30 p.m., Eastern Time, in New York City.
-
The Medicines Company is selling its infectious disease business unit to Melinta Therapeutics.
-
The Medicines Company Names Dr. Fred Eshelman as Executive Chairman; Appoints Geno Germano to Its Board of Directors
11/15/2017
These appointments are effective immediately.
-
The Medicines Company and Alnylam Pharmaceuticals Announce Initiation of Phase III Clinical Trials of Inclisiran
11/6/2017
The Medicines Company today announced the initiation of the Phase III clinical program for inclisiran, with the commencement of patient dosing on November 1, 2017 in the ORION-11 trial.
-
In addition to the layoffs, the company is also looking to divest its Infectious Disease Business.